CRISPR DNA Editing Can Cause Hundreds of Off-Target Mutations
By Dave Roos,
Seeker [cites Marcy Darnovsky]
| 06. 06. 2017
A new study offers a cautionary tale for using the widely hyped gene-editing tool CRISPR on people.
The gene-editing technology known as CRISPR has only been around for five years, but it’s already generated enough hype and controversy to last a lifetime. Compared to other gene-editing techniques, CRISPR is so fast, cheap, and precise that any scientist with a basic understanding of genetics can experiment with DNA — plant, animal, or human — by cutting out and replacing specific genes.
Some say that the ease and effectiveness of CRISPR will usher in a golden age of genetic modification resulting in new cures for inherited diseases like Huntington’s and muscular dystrophy and new gene therapies for eradicating cancer and HIV. Others see CRISPR as a Pandora’s box leading to a dystopian future of designer babies and expensive life-extending therapies that will further divide the world into genetic haves and have nots.
Now a new study complicates the CRISPR controversy by shining a light on CRISPR’s Achilles' heel — off-target mutations. CRISPR works by targeting short sequences of DNA base pairs in...
Related Articles
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By Amy Feldman, Forbes | 02.17.2026
"Jennifer Doudna" by Duncan Hull for the Royal Society via Wikimedia Commons licensed under CC by SA 3.0
Soon after KJ Muldoon was born in August 2024, he was lethargic and wouldn’t eat. His worried doctors realized his ammonia...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...